Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.76 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068441 | 1.00 | CRBN (0.76) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22326213 | 0.90 | CRBN (0.77) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30821747 | 0.90 | CRBN (0.70) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30144633 | 0.87 | CRBN (0.76) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30692345 | 0.87 | CRBN (0.82) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22689174 | 0.87 | CRBN (0.82) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30692346 | 0.87 | CRBN (0.82) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23173138 | 0.87 | CRBN (0.82) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29943347 | 0.87 | CRBN (0.71) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30805475 | 0.87 | CRBN (0.71) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | claimed |
| WO-2025021075-A1 | NSD PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国科学院上海有机化学研究所 | 2025-01-30 | — | — | WO | disclosed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | disclosed |
| WO-2022270994-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | 한국화학연구원 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022270994-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | 한국화학연구원 | 2022-12-29 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |